Overview
The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney transplant recipients (cPRA ≥90%).
Unicentric, randomized, open study.
Eligibility
Inclusion Criteria:
- Sensitized (cPRA ≥90%) candidates for a deceased-donor kidney transplantation
- Recipients between 18 and 75 years old
- Patients are able to understand and sign informed consent (Annex 1).
Exclusion Criteria:
- Participation in another interventional clinical trial.
- Use of Rituximab or Eculizumab at the time of transplant or in the first 24 hours post-transplant.
- Persons with any dependency on the researcher or employee by the responsible institution or researcher. As well as people detained by legal order.